Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ON101 Cream in Chronic Diabetic Foot Ulcers
NCT04962139Phase 3Terminated
- Sponsor
- Oneness Biotech Co., Ltd.
- Start
- Jul 2021
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in diabetic foot ulcer (DFU) comparing ON101 Cream with Vehicle Cream (2 arms). Primary endpoint: Proportion of subjects with complete closure of Target Ulcer at 20 weeks. Started Jul 2021; status: terminated.
02
Drugs
Fespixon
03
Conditions
diabetic foot ulcer (DFU)
Beyond the preview
Go deeper on NCT04962139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04962139.